Intravenous immunoglobulin (IVIG) in the vanguard therapy of Systemic Sclerosis.

导出 LinkOut

翻译打印收藏纠错

第一作者： João Pedro,Gomes

第一单位： Zabludowicz Center for Autoimmune Disease, Sheba Medical Center, Tel Hashomer, Israel; Department A of Internal Medicine, Hospital and University Centre of Coimbra, Coimbra, Portugal; Faculty of Medicine, University of Coimbra, Portugal. Electronic address: jpcxl@hotmail.com.

作者： João Pedro,Gomes ^[1] ; Lèlita,Santos ^[2] ; Yehuda,Shoenfeld ^[3]

作者单位： Zabludowicz Center for Autoimmune Disease, Sheba Medical Center, Tel Hashomer, Israel; Department A of Internal Medicine, Hospital and University Centre of Coimbra, Coimbra, Portugal; Faculty of Medicine, University of Coimbra, Portugal. Electronic address: jpcxl@hotmail.com. ^[1] Department A of Internal Medicine, Hospital and University Centre of Coimbra, Coimbra, Portugal; Faculty of Medicine, University of Coimbra, Portugal. Electronic address: lelitasantos@netcabo.pt. ^[2] Sackler Faculty of Medicine, Tel Aviv University, Israel; Zabludowicz Center for Autoimmune Disease, Sheba Medical Center, Tel Hashomer, Israel. Electronic address: shoenfel@post.tau.ac.il. ^[3]

关键词 Autoimmune diseases Autoimmunity Fibrosis Intravenous immunoglobulins (IVIG)Systemic sclerosis

主题词人类(Humans);免疫球蛋白类, 静脉内(Immunoglobulins, Intravenous);硬皮病, 系统性(Scleroderma, Systemic)

DOI 10.1016/j.clim.2018.12.006

PMID 30543921

发布时间 2019-12-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交